The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
The sellside’s protestations aside, results at the World Muscle meeting position risdiplam and AVXS-101 as serious challengers to Spinraza in spinal muscular atrophy.
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Other therapy areas take a back seat as the pharma industry continues to focus on cancer-focused licensing deals.
A complete response letter for Waylivra has taken investors by surprise, and increases the pressure on Ionis before an FDA decision on Tegsedi.
Pfizer eyes tafamidis approval in cardiac amyloidosis, but things could have been worse for its rivals, Alnylam and Ionis.
Ionis seeks a green light for Waylivra in a rare disease, but safety concerns could seriously hit sales. Meanwhile, Intra-Cellular needs a pivotal bipolar trial win for…